0001144204-17-026508.txt : 20170511 0001144204-17-026508.hdr.sgml : 20170511 20170511170804 ACCESSION NUMBER: 0001144204-17-026508 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170511 DATE AS OF CHANGE: 20170511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55723 FILM NUMBER: 17835338 BUSINESS ADDRESS: STREET 1: 15150 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 BUSINESS PHONE: 858-605-9055 MAIL ADDRESS: STREET 1: 15150 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 10-Q 1 v465791_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission file number: 000-55723

GUARDION HEALTH SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Delaware

15150 Avenue of Science, Suite 200

San Diego, California 92128

Telephone: 858-605-9055

47-4428421

(State or other jurisdiction

of incorporation or

organization)

(Address and telephone number of principal executive offices)

(I.R.S. Employer

Identification No.)

15150 Avenue of Science, Suite 200

San Diego, California 92128

Telephone: 858-605-9055

(Address and telephone number of principal executive offices)

Not applicable

(Former name, former address, and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
(Do not check if a smaller reporting company)		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨ Yes x No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes x No

As of May 10, 2017, there were outstanding 25,443,259 shares of the issuer’s common stock, $0.001 par value. Registrant’s common stock is not yet publicly traded.

TABLE OF CONTENTS

		Page No.
PART I – FINANCIAL INFORMATION

ITEM 1.	CONDENSED FINANCIAL STATEMENTS	4

	Balance Sheets – As of March 31, 2017 (Unaudited) and December 31, 2016	4

	Statements of Operations (Unaudited) – Three Months Ended March 31, 2017 and March 31, 2016	5

	Statement of Stockholders’ Deficiency (Unaudited) – Three Months Ended March 31, 2017	6

	Statements of Cash Flows (Unaudited) – Three Months Ended March 31, 2017 and March 31, 2016	7

	Notes to Financial Statements (Unaudited)	8

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	17

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	23

ITEM 4.	CONTROLS AND PROCEDURES	23

PART II – OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	24

ITEM 1A.	RISK FACTORS	24

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	24

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	25

ITEM 4.	MINE SAFETY DISCLOSURES	25

ITEM 5.	OTHER INFORMATION	25

ITEM 6.	EXHIBITS	25

SIGNATURES		26

Introductory Comment

Throughout this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” “our company,” “Guardion,” the “Company” and the “Registrant” refer to Guardion Health Sciences, Inc.

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (the “Report”) contains forward-looking statements. These statements relate to future events or future predictions, including events or predictions relating to our future financial performance, and are based on current expectations, estimates, forecasts and projections about us, our future performance, our beliefs and management’s assumptions. They are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “feel,” “confident,” “estimate,” “intend,” “predict,” “forecast,” “potential” or “continue” or the negative of such terms or other variations on these words or comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks described under “Risk Factors” that may cause the Company’s or its industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In addition to the risks described in Risk Factors, important factors to consider and evaluate in such forward-looking statements include: (i) general economic conditions and changes in the external competitive market factors which might impact the Company’s results of operations; (ii) unanticipated working capital or other cash requirements including those created by the failure of the Company to adequately anticipate the costs associated with acquisitions and other critical activities; (iii) changes in the Company’s corporate strategy or an inability to execute its strategy due to unanticipated changes; and (iv) the failure of the Company to complete any or all of the transactions described herein on the terms currently contemplated. As a result of these risks and uncertainties, many of which are described in greater detail in the Risk Factors discussion in our Annual Report on Form 10-K for the year ended December 31, 2016 (“Form 10-K”), there can be no assurance that the forward-looking statements contained in this Report will in fact transpire.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company will update or revise the forward-looking statements to the extent required by applicable law.

PART I – FINANCIAL INFORMATION

ITEM 1. CONDENSED FINANCIAL STATEMENTS

Guardion Health Sciences, Inc.

Condensed Balance Sheets

	March 31,			December 31,
	2017			2016
	(Unaudited)
Assets

Current assets
Cash	$	444,850		$	62,520
Accounts receivable		1,914			1,673
Inventories		50,024			43,999
Current portion of deposits and prepaid expenses		37,732			29,363

Total current assets		534,520			137,555

Deposits and prepaid expenses, less current portion		10,470			10,470
Property and equipment, net		98,474			114,020

Total assets	$	643,464		$	262,045

Liabilities and Stockholders’ Deficiency

Current liabilities
Accounts payable and accrued liabilities	$	433,549		$	356,467
Accrued expenses and deferred lease costs		59,835			88,290
Due to related parties		133,388			91,483
Current portion of convertible notes payable		45,063			44,323
Current portion of promissory notes payable		125,433			10,251
Current portion of promissory notes payable related party		-			16,805

Total current liabilities		797,268			607,619

Commitments and contingencies

Stockholders’ Deficiency

Series A preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,705,154 and 1,705,154 shares issued and outstanding at March 31, 2017 and December 31, 2016		1,705			1,705
Series B preferred stock, $0.001 par value; 2,000,000 shares authorized; 700,000 issued and outstanding at March 31, 2017		700			-
Common stock, $0.001 par value; 90,000,000 shares authorized; 25,268,259 and 25,046,438 shares issued and outstanding at March 31, 2017 and December 31, 2016		25,269			25,046
Additional paid-in capital		21,205,658			20,277,882
Accumulated deficit		(21,387,136	)		(20,650,207	)

Total stockholders’ deficiency		(153,804	)		(345,574	)

Total liabilities and stockholders’ deficiency	$	643,464		$	262,045

See accompanying notes to condensed financial statements.

Guardion Health Sciences, Inc.

Condensed Statements of Operations

	Three Months Ended March 31,
	2017			2016
	(Unaudited)			(Unaudited)
Revenue	$	55,941		$	29,134

Cost of goods sold		22,633			14,247

Gross profit		33,308			14,887

Operating expenses
Research and development		10,239			10,172
Sales and marketing		76,736			103,578
General and administrative		598,913			623,956

Total operating expenses		685,888			737,706

Loss from operations		(652,580	)		(722,819	)

Other expenses:
Interest expense		16,431			226,384

Total other expenses		16,431			226,384

Net loss		(669,011	)		(949,203	)

Adjustments related to Series A and Series B convertible preferred stock:
Accretion of deemed dividend		(31,841	)		-
Dividend declared		(36,077	)		-
Net loss attributable to common shareholders	$	(736,929	)	$	(949,203	)

Net loss per common share – basic and diluted	$	(0.03	)	$	(0.05	)
Weighted average common shares outstanding – basic and diluted		24,760,327			20,966,396

See accompanying notes to condensed financial statements.

Guardion Health Sciences, Inc.

Condensed Statement of Stockholders’ Deficiency

(Unaudited)

	Series A Preferred Stock				Series B Preferred Stock				Common Stock
	Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-In Capital		Accumulated Deficit			Total Stockholders’ Deficiency
Balance at December 31, 2016		1,705,154	$	1,705		-	$	-		25,046,438	$	25,046	$	20,277,882	$	(20,650,207	)	$	(345,574	)
Issuance of common stock for services		-		-		-		-		162,500		163		160,618		-			160,781
Issuance of preferred stock		-		-		700,000		700		-		-		699,300		-			700,000
Accretion of beneficial conversion feature on preferred stock		-		-		-		-		-		-		31,841		(31,841	)		-
Dividend on preferred stock		-		-		-		-		59,321		60		36,017		(36,077	)		-
Net loss		-		-		-		-		-		-		-		(669,011	)		(669,011	)
Balance at March 31, 2017		1,705,154	$	1,705		700,000	$	700		25,268,259	$	25,269	$	21,205,658	$	(21,387,136	)	$	(153,804	)

See accompanying notes to condensed financial statements.

Guardion Health Sciences, Inc.

Condensed Statements of Cash Flows

	Three Months Ended March 31,
	2017			2016
	(Unaudited)			(Unaudited)
Operating Activities
Net loss	$	(669,011	)	$	(949,203	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		15,545			8,492
Amortization of debt discount		-			109,455
Accrued interest expense included in notes payable		13,116			17,148
Fair value of warrants issued as post-maturity interest		-			99,782
Stock-based compensation		103,623			8,127
Stock-based compensation – related parties		57,158			240,892
Changes in operating assets and liabilities:
(Increase) decrease in -
Accounts receivable		(240	)		15
Inventories		(6,025	)		(10,465	)
Deposits and prepaid expenses		(8,369	)		11,361
Increase (decrease) in -
Accounts payable and accrued expenses		77,083			122,454
Accrued and deferred rent costs		(28,456	)		(21,920	)

Net cash used in operating activities		(445,576	)		(363,862	)

Investing Activities
Purchase of property and equipment		-			(1,171	)

Net cash used in investing activities		-			(1,171	)

Financing Activities
Proceeds from issuance of convertible notes payable		-			136,000
Proceeds from issuance of promissory notes – related party		-			90,000
Proceeds from issuance of promissory notes		100,000			25,000
Payments on promissory notes		(14,000	)		-
Proceeds from issuance of preferred stock		700,000			-
Increase in due to related parties		41,906			85,300

Net cash provided by financing activities		827,906			336,300

Cash:
Net increase (decrease)		382,330			(28,733	)
Balance at beginning of period		62,520			13,850
Balance at end of period	$	444,850		$	(14,883	)

Supplemental disclosure of cash flow information:
Cash paid for -
Interest	$	-		$	-
Income taxes	$	-		$	-

Non-cash financing activities:
Fair value of warrants issued in connection with promissory and convertible notes payable	$	-		$	124,710
Beneficial conversion feature associated with promissory and convertible notes payable	$	-		$	39,774

See accompanying notes to condensed financial statements.

Guardion Health Sciences, Inc.

Notes to Financial Statements

(Unaudited)

Three Months Ended March 31, 2017 and 2016

Organization and Business Operations

Organization and Business

Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc.

The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z^® that replenishes and restores the macular protective pigment.

Through March 31, 2017, the Company has had limited operations, but has been primarily engaged in research and development and capital raising. The Company has incurred significant expenditures for the development of the Company's products and intellectual property, which includes research and development of both medical foods and medical diagnostic equipment for the treatment of various eye diseases. The Company had limited revenue during the three months ended March 31, 2017 and 2016, all of which was generated by the sale of the Company’s proprietary product, Lumega-Z. In late 2014, the Company changed its focus from the dietary supplement category to the medical food category based on consultation with the Company’s intellectual property counsel and regulatory affairs consultants, as a result of which Lumega-Z is now categorized and sold as a medical food.

Going Concern and Liquidity

The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $669,011 and utilized cash in operating activities of $445,576 during the three months ended March 31, 2017, and had a stockholders’ deficit of $153,804 as of March 31, 2017. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.

The Company’s auditors have also included explanatory language in their opinion that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.

Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition

The Company’s revenue is comprised of sales of medical foods to consumers through a direct sales/credit card process. Revenue is recognized when the risk of loss transfers to our customers, and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed.

The Company allows for returns within 30 days of purchase. Product returns for the three months ended March 31, 2017 and 2016 were insignificant.

Research and Development Costs

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $10,239 and $10,172 for the three months ended March 31, 2017 and 2016, respectively.

Stock-Based Compensation

The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers and directors, and to employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future.

The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm whose input was utilized in determining the related per unit or share valuations of the Company’s equity instruments. Management used valuations of $1.00 per unit or share in its fair value calculations for the periods between January 1, 2016 and September 30, 2016, and $0.88 per share for periods after September 30, 2016. The current valuation of $0.88 per share is lower than previous valuations due to the dilutive effect of the issuance of common shares as compensation during the periods. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. The Company considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:

	Three Months Ended March 31,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Management considered business and market factors affecting the Company during the three-month periods ended March 31, 2017 and 2016, including capital raising efforts, its proprietary technology, and other factors. Based on this evaluation, management believes that $0.88 and $1.00 per share valuations are appropriate for accounting purposes for the periods ending March 31, 2017 and 2016, respectively.

The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The Company recognizes stock compensation expense on stock or unit purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock or units over the price paid for the stock or units.

The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.

Income Taxes

The Company currently accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.

The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of March 31, 2017, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.

The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.

Net Loss per Share

The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share.

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	March 31,
	2017		2016
Warrants		2,983,666		2,251,166
Estimated shares issuable upon conversion of convertible notes payable		31,250		1,445,811
Shares issuable upon conversion of convertible preferred stock		3,775,266		-
		6,790,182		3,696,977

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures.

In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 has not had any impact on the Company’s financial statement presentation or disclosures.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Inventories

Inventories consisted of the following:

	March 31,		December 31,
	2017		2016
Raw materials	$	43,987	$	40,679
Finished goods		6,037		3,320
	$	50,024	$	43,999

Property and Equipment, net

Property and equipment consisted of the following:

	March 31,			December 31,
	2017			2016
Leasehold improvements	$	98,357		$	98,357
Testing equipment		145,503			145,503
Furniture and fixtures		15,348			15,348
Computer equipment		15,277			15,277
Office equipment		2,694			2,694
		277,179			277,179
Less accumulated depreciation and amortization		(178,705	)		(163,159	)
	$	98,474		$	114,020

For the three months ended March 31, 2017 and 2016, depreciation and amortization expense was $15,545 and $8,492, respectively, of which $7,325 and $5,515 was included in research and development expense, respectively, and $8,220 and $2,977 was included in general and administrative expense, respectively.

Convertible Notes Payable

	March 31,		December 31,
Year of issuance:	2017		2016
2010 (due August 2013)	$	25,000	$	25,000
Accrued interest		20,063		19,323
Notes payable	$	45,063	$	44,323

In July 2010, the Company issued an unsecured convertible note payable in the amount of $25,000. The note carries simple interest at a rate of 12% per annum and became due and payable on August 1, 2013. The outstanding amounts are convertible into shares of common stock of the Company at conversion prices of $0.08 per share. This note is currently outstanding and past due, and $20,063 of accrued interest is recorded as of March 31, 2017.

Promissory Notes

	March 31,		December 31,
Year of issuance:	2017		2016
(a) 2016 (due November 2016)	$	10,000	$	10,000
(b) 2017 (due May 2017)		100,000		-
Accrued interest		15,433		251
Promissory notes payable, net	$	125,433	$	10,251

(a) In 2016, the Company issued $170,000 of promissory notes to various outside investors, with simple interest rates ranging from 4% - 9% and a weighted average term at issuance of approximately three months. As of March 31, 2017 and December 31, 2016, a $10,000 note remained outstanding and was past due, and $350 and $251 of accrued interest is recorded as of March 31, 2017 and December 31, 2016.

(b) In January 2017, the Company issued a $100,000 unsecured promissory note to an outside investor, with a term of 120 days and a fixed interest charge consisting of 6% of the principal in cash plus 6% of the principal in shares of common stock at a price of $0.75 per share, or 8,000 shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $13,040, representing the total fair value of the charge, at the inception of the note.

Promissory Notes – Related Party

	March 31,		December 31,
Year of issuance:	2017		2016
2016 (due September 2016)	$	-	$	14,000
Accrued interest		-		2,805
Promissory notes payable – related party, net	$	-	$	16,805

In 2016, the Company issued $140,000 of unsecured promissory notes to various related party investors, with interest rates ranging from 6% to 12% and a weighted average term at issuance of approximately four months. As of December 31, 2016 the remaining balance of the unpaid notes was $14,000, which was repaid during the first quarter of 2017.

Commitments and Contingencies

The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed financial statements at March 31, 2017 with respect to such matters, including the matter noted below.

The Company recently received a payment demand from a former consultant to the Company alleging that he is owed $102,000 for unpaid services rendered. The Company is evaluating the claim and intends to respond to the former consultant’s demand in due course. If this matter results in the filing of a lawsuit against the Company, the Company intends to vigorously defend itself and, as well, will consider filing a counterclaim for damages against the former consultant.

Stockholders’ Deficit

Preferred Stock

Series A

During 2016, the Company sold 1,170,000 shares of the Company’s Series A Senior Convertible Preferred Stock to various investors. The purchase price of the stock was $1.00 per share, for an aggregate purchase price of $1,170,000. In addition, the Company issued 535,154 shares of its preferred stock with a fair value of $784,888 upon conversion of $535,149 of notes payable and accrued interest. The stock has a stated value of $1.00 per share and accrues an annual dividend at the rate of 8% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $0.60 per share. Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative.

At the option of the holder, the Series A preferred stock (including accrued but unpaid dividends) may be converted into shares of the Company’s common stock commencing January 1, 2017 at $0.60 per share. The preferred stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more. If not converted by September 30, 2019, the preferred stock (including accrued but unpaid dividends) shall automatically and mandatorily convert into shares of common stock at $0.60 per share. Such mandatory conversion shall be subject to either a registration statement having been filed with the Securities and Exchange Commission, including the common stock underlying the preferred stock, and being in effect, or all shares of underlying common stock being saleable under Rule 144 pursuant to the Securities Act without regard to volume limitations.

The issuance of the 1,170,000 shares of convertible preferred stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.60 per share being less than the market price of the shares at the issuance date as determined by a third-party valuation. The Company accounted for the beneficial conversion features in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series A Senior Convertible Preferred Stock of $779,586 at December 31, 2016, which equals the amount by which the estimated fair value of the common stock issuable upon conversion of the issued preferred stock exceeded the proceeds from such issuances. The deemed dividend on the preferred stock is accreted using the effective interest method from the respective issuance dates through the earliest conversion date of January 1, 2017. The accretion of the deemed dividend for the year ended December 31, 2016 was $760,011. The remaining balance of $19,575, representing the amount allocable to the January 1, 2017 earliest conversion date, was accreted in January 2017.

Sale of the Company’s Series A Senior Convertible Preferred Stock was closed on December 31, 2016.

During the three months ended March 31, 2017 the Company declared dividends of $ 33,631 to its Series A preferred shareholders which were paid through the issuance of 56,065 shares of common stock.

Series B

As of May 10, 2017, the Company had sold 700,000 shares of the Company’s Series B Convertible Preferred Stock to various investors. The purchase price of the stock was $1.00 per share, for an aggregate purchase price of $700,000. The stock has a stated value of $1.00 per share and accrues an annual dividend at the rate of 6% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $0.75 per share. Series B preferred stock is convertible commencing December 31, 2017, or earlier upon the approval of the Board of Directors, by the holder into common stock at $0.75 per share. The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation). Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative. Series B preferred stock is senior to all Common Stock and junior to the Series A preferred stock.

The issuance of the Series B preferred stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.75 per share being less than the market price of the shares at the issuance date. In addition, warrants were issued to investors who had previously participated in the 2016 Series A preferred stock offering. The Company accounted for the beneficial conversion feature, including an allocation of proceeds for the warrants on a relative fair value basis, in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series B preferred stock of $165,506 at March 31, 2017, which equals the amount by which the estimated fair value of the common stock issuable upon conversion of the issued preferred stock exceeded the proceeds from such issuances. The deemed dividend on the preferred stock is accreted using the effective interest method from the respective issuance dates through the earliest conversion date of December 31, 2017. The accretion of the deemed dividend for the three months ended March 31, 2017 was $12,266.

During the three months ended March 31, 2017, the Company declared dividends of $2,441 to its Series B preferred shareholders which were paid through the issuance of 3,256 shares of common stock.

Both classes of preferred stock will vote with the common stock on an “as converted” basis and have standard anti-dilution rights, exclusive of price protection. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, no distribution shall be made to the holders of any shares of common stock of the Company unless, prior thereto, the holders of all classes of preferred stock shall have received out of the available assets of the Company, whether capital or surplus, an amount equal to 100% of the stated value, plus any accrued and unpaid dividends thereon. If the assets of the Company are insufficient to pay in full such amounts due the holders of the preferred stock, then the entire assets shall be distributed ratably among the holders of the preferred stock in accordance with the respective preferences and amounts that would be payable on such shares of preferred stock if all amounts payable thereon were paid in full.

Preferred shareholders of both series have unlimited piggyback registration rights. Holders of a majority of the shares of preferred stock (based on the $1.00 stated value) outstanding shall have the right to one demand registration during the three (3) years following the effective date of the Company’s registration statement under the Securities Exchange Act of 1934, so long as at least $500,000 of preferred stock was sold of that series, and at least $250,000 of the related class of preferred stock is still outstanding. This demand registration right will terminate when all shares of preferred stock have been converted into common stock.

In the event of a merger or acquisition or change in control of the Company, the preferred stock (including all accrued but unpaid dividends) will be deemed converted into shares of common stock immediately prior to the closing of such a transaction.

Common Stock

During 2016 and prior, the Company issued 2,005,000 shares of restricted common stock for services rendered. These shares are subject to vesting requirements over 9 to 12 months and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock was $2,146,280. As of December 31, 2016, 1,652,500 of those shares with a fair value of $2,037,014 had vested, and 352,500 shares with a fair value of $109,266 remained to be vested.

During the three months ended March 31, 2017, the Company recorded $1,160,781 of expense related to the vested portion of this restricted stock, and the remaining $91,485 is expected to be recorded in the second quarter of 2017.

Additional details of the Company’s restricted common stock are as follows:

	Number of Shares			Weighted Average Grant Date Fair Value Per Share
Non-vested, December 31, 2016		352,500			1.13
Issued		162,500			0.88
Vested		(123,750	)		0.92
Forfeited		-			-
Non-vested, March 31, 2017		391,250		$	1.09

Warrants

During the three months ended March 31, 2017, in connection with the Series B Convertible Preferred Stock offering discussed above, the Company issued a total of 60,000 warrants as additional incentive to investors who had previously invested in the Company’s Series A Senior Convertible Preferred Stock offering in 2016. These warrants are fully vested, are immediately exercisable at $0.75 per share, and expire between March 6, 2020 and March 8, 2020. The warrants were valued at $51,796, based upon the Black-Scholes option-pricing model, with a stock price of $0.88, volatility of 135%, and an average risk-free interest rate of 1.61%.

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2016		2,923,666
Granted		60,000
Forfeitures		-
Exercised		-
March 31, 2017, all exercisable		2,983,666

As of March 31, 2017, the Company had an aggregate of 2,983,666 outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $0.37, weighted average remaining life of 1.4 years and aggregate intrinsic value of $1,293,512, based upon a stock valuation of $0.88 per share. The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the warrants.

10.

Related Party Transactions

Due to and from related parties represents unreimbursed expenses and compensation incurred on behalf of, and amounts loaned to the Company by, Michael Favish, the Company’s Chief Executive Officer, as well as other shareholders. The advances are unsecured, non-interest bearing and are due on demand. As of March 31, 2017 and December 31, 2016, the Company had $133,388 and $91,483, respectively, due to related parties.

During the three months ended March 31, 2017, the Company incurred $62,500 of salary expense and paid $22,500 for our CEO, Michael Favish. During the twelve-month period ended December 31, 2016, the Company incurred salary expense of $250,000 and paid $48,500. Accrued amounts are included in general and administrative expenses.

11.

Subsequent Events

During April 2017, the Company issued 175,000 shares of fully vested restricted common stock to consultants for services rendered.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Presentation of Information

As used in this Quarterly Report on Form 10-Q, the terms “we,” “us” “our” and the “Company” mean Guardion Health Sciences, Inc. unless the context requires otherwise. The following discussion and analysis should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this report. All dollar amounts refer to U.S. dollars unless otherwise indicated.

Overview

Guardion Health Sciences, Inc. was formed in December 2009 in California as a limited liability company under the name P4L Health Sciences, LLC and we subsequently changed our name to Guardion Health Sciences, LLC. On June 30, 2015, we converted from a California limited liability company to a Delaware corporation, changing our name to Guardion Health Sciences, Inc.

We are a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z^® that replenishes and restores the macular protective pigment. A depleted macular protective pigment is a modifiable risk factor for retina based diseases such as age-related macular degeneration (“AMD”), computer vision syndrome (“CVS”) and diabetic retinopathy. Additional research has also shown a depleted macular protective pigment to be a biomarker for neurodegenerative diseases such as Alzheimer’s and dementia. We have had limited commercial operations to date, and have primarily been engaged in research and development.

We have also developed a proprietary medical device called the MapcatSF^®that accurately measures the macular pigment optical density (“MPOD”). We invented our own proprietary patented technology embodied in the MapcatSF. On November 8, 2016, the USPTO issued patent number 9,486,136 for the MapcatSF invention. Using the MapcatSF to measure the MPOD allows one to monitor the increase in the density of the macular protective pigment after taking Lumega-Z. The MapcatSF is a non-mydriatic, non-invasive device that accurately measures the MPOD, the lens optical density and lens equivalent age, thereby creating an evidence-based protocol that is shared with the patient. A non-mydriatic device is one that does not require dilation of the pupil for it to function. The MapcatSF is intended to be the first device using a patented “single fixation” process and “automatic lens density correction” that produces accurate serialized data.

Lumega-Z has a patent-pending formula that replenishes and restores the macular protective pigment simultaneously delivering critical and essential nutrients to the eye. Formulated by Dr. Sheldon Hendler in 2010, modifications were made over a two-year period to improve the taste and method of delivery. We believe that there is an increasing level of acceptance of medical foods as a primary therapy by patients and healthcare providers to treat pain syndromes, sleep and cognitive disorders, obesity, hypertension, and viral infection. In clinical practice, medical foods are being prescribed as both a standalone therapy and as an adjunct therapy to low doses of commonly prescribed drugs. We believe that medical foods will continue to grow in importance over the coming years.

By combining our MapcatSF medical device and Lumega-Z medical food, we have developed, based on Management’s knowledge of the industry, the only reliable two-pronged, evidence-based protocol for replenishing and restoring the macular protective pigment and increasing overall retinal health.

Recent Developments

On March 1, 2017, we entered into a non-binding letter of intent (“LOI”) with VectorVision, Inc., a Delaware corporation (“VectorVision”), whereby the parties set forth an outline of the terms and conditions pursuant to which we would acquire all of the outstanding shares of stock of VectorVision in exchange for a to be determined number of shares of our common stock. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision’s CSV-1000 device is considered the standard of care for clinical trials. Upon closing of the transaction, VectorVision would become a wholly-owned subsidiary of ours. We believe the acquisition of VectorVision would expand our technical portfolio and further establish our position at the forefront of early detection, intervention and monitoring of a range of eye diseases. The transaction is subject to significant conditions precedent to closing, including, but not limited to, the satisfactory completion of due diligence, the determination of the amount of purchase consideration, the negotiation of definitive transaction documents, the completion of an audit of VectorVision’s financial statements, and other matters, no later than the June 30, 2017 expiration date of the LOI.

Going Concern

The financial statements have been prepared assuming we will continue as a going concern. We have utilized cash in operating activities of $445,576 and $363,862 during the three months ended March 31, 2017 and 2016, respectively, and had a total stockholders’ deficiency of $153,804 and $345,574 as of March 31, 2017 and December 31, 2016, respectively. We expect to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about our ability to continue as a going concern within one year of the date that the financial statements are issued.

Our auditors have also included explanatory language in their opinion that there is substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of us to continue as a going concern.

We will continue to incur significant expenses for commercialization activities related to our lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build our infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, our long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. We are continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that we will be able to secure such additional financing in the amounts necessary to fully fund our operating requirements on acceptable terms or at all. If we are unable to access sufficient capital resources on a timely basis, we may be forced to reduce or discontinue our technology and product development programs and curtail or cease operations.

Recent Accounting Pronouncements

See Note 1 to the condensed financial statements for Managements’ discussion of recent accounting pronouncements.

Critical Accounting Policies and Estimates

Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Our financial statements included herein include all adjustments, consisting of only normal recurring adjustments, necessary to present fairly our financial position, results of operations and cash flows.

The following critical accounting policies affect the more significant judgments and estimates used in the preparation of our financial statements.

Stock-Based Compensation

We periodically issue stock-based compensation to officers, directors, and other consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers and directors, and to employees in the future which will include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until we have established a trading market for our common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; we have never declared or paid dividends on our common stock and have no plans to do so for the foreseeable future.

The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, we retained a third-party valuation firm in determining the value of our Company. The third-party valuation firm’s input was utilized in determining the related per unit or share valuations of our equity used at March 31, 2017 and December 31, 2016. Management used valuations of $1.00 per unit or share in its fair value calculations for the periods between January 1, 2016 and September 30, 2016, and $0.88 per share for periods after September 30, 2016, based on various inputs, including valuation reports prepared by the third-party valuation firm as of December 31, 2016 and 2015. The fully diluted per share equivalent price is lower in 2017 than in early 2016 due to the dilutive effect of the issuance of common shares as compensation during the period. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. We considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:

	Three Months Ended March 31,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Management considered business and market factors affecting us during the three-month periods ended March 31, 2017 and 2016, including capital raising efforts, its proprietary technology, and other factors. Based on this evaluation, management believes that $0.88 and $1.00 per share valuations are appropriate for accounting purposes at March 31, 2017 and December 31, 2016.

We account for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

We recognize stock compensation expense on stock or unit purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock or units over the price paid for the stock or units.

We recognize the fair value of stock-based compensation within our statements of operations with classification depending on the nature of the services rendered. We issue new shares to satisfy stock option exercises.

During the three months ended March 31, 2017 and 2016, we recognized aggregate stock-compensation expense of $160,781 and $249,019, respectively, based upon stock prices ranging from $0.88 to $1.14 per share, of which $150,288 and $199,146 was recorded in general and administrative expense, $10,179 and $48,178 was recorded in sales and marketing expense, and $314 and $1,695 was recorded in research and development expense, respectively.

Plan of Operations

General Overview

Based on the availability of sufficient funding, we intend to increase our commercialization activities and:

further the commercial production of our MapcatSF, starting with the manufacture of at least ten new units for sale or lease to our customers and for use in our internal clinics;

expand our domestic sales and marketing efforts, which include revamping our web site and new promotional materials;

increase production of Lumega-Z as is necessary to support the additional sales resulting from the deployment of additional MapcatSF units and increased marketing and promotional activity;

commence certain FDA electrical safety testing of the MapcatSF; and

increase our focus on intellectual property protection and strategy.

The FDA and other regulatory bodies require electronic medical devices to comply with IEC 60601 standards. The International Electrical Commission (“IEC”) established technical standards for the safety and effectiveness of medical electrical equipment. Adherence to these standards is required for commercialization of electrical medical equipment. As a medical device powered by electricity, the MapcatSF will need to undergo testing to demonstrate compliance with the IEC 60601 standards. This testing is typically conducted by a Nationally Recognized Testing Laboratory (“NRTL”), which is an independent laboratory recognized by the Occupational Safety and Health Administration (“OSHA”) to test products to the specifications of applicable product safety standards. We are in discussions with our contract manufacturer of the MapcatSF to engage an NRTL at the appropriate juncture prior to commercialization of the MapcatSF. The relevant predicate device for the MapcatSF is the MPS II, the applicable Class I product code for the MapcatSF is HJW and the applicable Code of Federal Regulation is 886.1050. The FDA does not require test documents to be submitted to the FDA for a Class I medical device, but that the evidence of such testing be placed in a Design History file and be kept internally at the Company or manufacturer and readily available should the FDA or other regulatory bodies request to review the testing documents. While the FDA does not require that a Class I medical device have formal validation, we expect to complete applicable IEC 60601-1 testing prior to commercialization as we believe in marketing a product that has evidence that it is safe and effective.

Results of Operations

Through March 31, 2017, we had limited operations and have primarily been engaged in research and development and raising capital. We have incurred significant expenditures for the development of our products and intellectual property, which includes research and development of both medical foods and medical diagnostic equipment for the treatment of various eye diseases. We had limited revenue during the three-month periods ended March 31, 2017 and 2016, all of which was generated by the sale of our proprietary product, Lumega-Z. In late 2014, we changed our focus from the dietary supplement category to the medical food category based on consultation with our intellectual property counsel and regulatory affairs consultants, as a result of which Lumega-Z is now categorized and sold as a medical food

Comparison of Three Months Ended March 31, 2017 and 2016

	Three Months Ended December 31,
	2017			2016			Change
Revenue	$	55,941		$	29,134		$	26,807		92	%
Cost of goods sold		22,633			14,247			8,386		59	%
Gross Profit		33,308			14,887			18,421		124	%
Operating Expenses:
Research and development		10,239			10,172			67		1	%
Sales and marketing		76,736			103,578			(26,842	)	(26	)%
General and administrative		598,913			623,956			(25,043	)	(4	)%
Total Operating Expenses		685,888			737,706			(51,818	)	(7	)%
Loss from Operations		(652,580	)		(722,819	)		70,239		(10	)%
Other Expense:
Interest expense		16,431			226,384			(209,953	)	(93	)%
Net Loss	$	(669,011	)	$	(949,203	)	$	280,192		(30	)%

Revenue

For the three months ended March 31, 2017, revenue from the sale of Lumega-Z was $55,941 compared to $29,134 for the three months ended March 31, 2016, resulting an increase of $26,807 or 92%. The increase is reflective of an increased customer base as we expand into new clinics.

Cost of Goods Sold

For the three months ended March 31, 2017, cost of goods sold from the sale of Lumega-Z was $22,633 compared to $14,247 for the three months ended March 31, 2016, resulting an increase of $8,386 or 59%. The increase corresponds to the additional sales recorded in 2017.

Research and Development

For the three months ended March 31, 2017, research and development costs were $10,239, consistent with the $10,172 cost from the comparable period in 2016.

Sales and Marketing

For the three months ended March 31, 2017, sales and marketing expenses were $76,736 compared to $103,578 for the comparable period in 2016. The decrease in sales and marketing expenses of $26,842 or 26% compared to the prior period was due primarily to a decrease in non-cash stock compensation expense.

General and Administrative

For the three months ended March 31, 2017, general and administrative expenses were $598,913 compared to $623,956 for the three months ended March 31, 2016. The decrease of $25,043 or 4% compared to the prior period was primarily due to a $48,859 reduction in non-cash stock compensation expense from the prior period, partially offset by an increase in accrued legal and management fees.

Interest Expense

For the three months ended March 31, 2017, interest expense was $16,431 compared to $226,384 for the comparable period of 2016. The decrease in interest expense of $209,953 or 93% compared to the prior year was due to the settlement, during 2016, of the majority of promissory notes and convertible debt that had been outstanding at the end of 2015.

Net Loss

For the three months ended March 31, 2017, we incurred a net loss of $669,011, compared to a net loss of $949,203 for the three months ended March 31, 2016. The decrease in net loss of $280,192 or 30% compared to the prior year period was primarily due to the reduction of $209,953 in interest expense related to promissory notes and convertible debt that was settled in 2016, as well as to reduced stock compensation expense in the current quarter ($160,781 was recognized in the current quarter versus $249,019 in the prior year period).

Liquidity and Capital Resources

Since our formation in 2009, we have devoted substantial effort and capital resources to the development and commercialization activities related to our lead product Lumega-Z and our MapcatSF medical device. As a result of our activities we utilized cash in operating activities of $445,576 during the three months ended March 31, 2017. We had negative working capital of $262,748 at March 31, 2017. As of March 31, 2017, we had cash in the amount of $444,850 and no available borrowings. Our financing has historically come from the issuance of convertible notes and promissory notes and to a lesser extent from the sale of common and preferred stock and exercise of warrants.

The financial statements have been prepared assuming we will continue as a going concern. We expect to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about our ability to continue as a going concern within one year of the date that the financial statements are issued.

We will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build our infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, our long-term viability and growth will depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. We are continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that we will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If we are unable to access sufficient capital resources on a timely basis, we may be forced to reduce or discontinue its technology and product development programs and ultimately curtail or cease operations.

Sources and Uses of Cash

The following table sets forth our major sources and uses of cash for each of the following periods:

	Three Months Ended March 31,
	2017			2016
Net cash used in operating activities	$	(445,576	)	$	(363,862	)
Net cash used in investing activities		-			(1,171	)
Net cash provided by financing activities		827,906			336,300
Net increase (decrease) in cash	$	382,330		$	(28,733	)

Operating Activities

Net cash used in operating activities was $445,576 during the three months ended March 31, 2017, versus $363,862 used during the comparable prior year period. The increase in 2017 was due primarily to additional general and administrative costs paid for consulting and other professional services.

Investing Activities

Net cash used in investing activities was $0 for the three months ended March 31, 2017 and $1,171 for the three months ended March 31, 2016, and consisted of investment in property and equipment.

Financing Activities

Net cash provided by financing activities was $827,906 for the three months ended March 31, 2017. Financing activities for the 2017 period provided proceeds of $100,000 from the issuance of short-term loans partially offset by payments on those loans of $14,000, $700,000 in proceeds from the issuance of preferred stock, and $41,906 in amounts due to related parties on a net basis.

Net cash provided by financing activities was $336,300 the year ended March 31, 2016. Financing activities for 2016 provided proceeds of $251,000 from the issuance of convertible notes and promissory notes, and $85,300 in amounts due to related parties on a net basis.

Off-Balance Sheet Arrangements

At March 31, 2017 and December 31, 2016, we did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Accounting Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon this evaluation, the Chief Executive Officer and Chief Accounting Officer each concluded that the Company’s disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms, and that such information has been accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Accounting Officer, in a manner that allows timely decisions regarding required disclosure. There have been no changes in the Company’s internal control over financial reporting identified in connection with the evaluation that occurred during the first quarter ended in 2017 that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 1A. RISK FACTORS

As of the date of this filing, there have been no material changes to the Risk Factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed with the SEC on March 30, 2017 (the “2016 Form 10-K”). The Risk Factors set forth in the 2016 Form 10-K should be read carefully in connection with evaluating the Company’s business and in connection with the forward-looking statements contained in this Quarterly Report on Form 10-Q. Any of the risks described in the 2016 Form 10-K could materially adversely affect the Company’s business, financial condition or future results and the actual outcome of matters as to which forward-looking statements are made. These are not the only risks that the Company faces. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended March 31, 2017, the Company sold 700,000 shares of the Company’s Series B Convertible Preferred Stock to various investors. The purchase price of the stock was $1.00 per share, for an aggregate purchase price of $700,000. The stock has a stated value of $1.00 per share and accrues an annual dividend at the rate of 6% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $0.75 per share. Series B preferred stock is convertible commencing December 31, 2017, or earlier upon the approval of the Board of Directors, by the holder into common stock at $0.75 per share. The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation). Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative. Series B preferred stock is senior to all Common Stock and junior to the Series A preferred stock.

During the three months ended March 31, 2017, in connection with the Series B Convertible Preferred Stock offering, the Company issued a total of 60,000 warrants as additional incentive to investors who had previously invested in the Company’s Series A Senior Convertible Preferred Stock offering in 2016. These warrants are fully vested, are immediately exercisable at $0.75 per share, and expire between March 6, 2020 and March 8, 2020. The warrants were valued at $51,796, based upon the Black-Scholes option-pricing model, with a stock price of $0.88, volatility of 135%, and an average risk-free interest rate of 1.61%.

The offerings of Series A Preferred Stock and Series B Preferred Stock were exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D and/or Regulation S promulgated thereunder. No sales commissions were paid in connection with these transactions and no placement agent or underwriter was involved.

During the three months ended March 31, 2017, the Company issued 162,500 shares of restricted common stock to a service provider. These shares are subject to vesting requirements over 4 months and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock was $143,000 based on a valuation per share of $0.88 on the date of grant. During the three months ended March 31, 2017, the Company recorded $100,833 of expense related to the vested portion of this restricted stock. The securities issued in the above transaction were exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, as such transaction did not involve any public offering. No sales commissions were paid in connection with this transaction and no placement agent or underwriter was involved.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which is presented elsewhere in this document, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 11th day of May, 2017.

	GUARDION HEALTH SCIENCES, INC.

	By:	/s/ Michael Favish
	Name:	Michael Favish
	Title:	Chief Executive Officer

POWER OF ATTORNEY

We, the undersigned officers and directors of GUARDION HEALTH SCIENCES, INC., hereby severally constitute and appoint Michael Favish and Vincent J. Roth, and each of them (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution, for us in any and all capacities, to sign any amendments to this Form 10-Q, and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Michael Favish	CEO, President and	May 11, 2017
Michael Favish	Chairman of the Board (Principal Executive Officer)

/s/ John Townsend	Controller and Chief Accounting Officer	May 11, 2017
John Townsend	(Principal Accounting Officer)

INDEX TO EXHIBITS

Exhibit No.			Description
3.1			Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of Series A Convertible Preferred Stock with Certificate of Correction (1)
3.2			Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of Series B Convertible Preferred Stock (2)
4.1			Form of Preferred Stock Purchase Agreement (1)
4.2			Form of Series B Preferred Stock Purchase Agreement (2)
31.1			Certification of Chief Executive Officer pursuant to Rule 13a – 14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2			Certification of Chief Accounting Officer pursuant to Rule 13a – 14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1			Certification of Chief Executive Officer and Chief Accounting Officer pursuant to 18.U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002
101			The following materials from the Company’s Quarterly Report on Form 10-Q for the year ended March 31, 2017, formatted in XBRL (eXtensible Business Reporting Language), (i) Balance Sheets, (ii) Statements of Income, (iii) Statements of Comprehensive Income, (iv) Statements of Cash Flows, (v) Statement of Stockholders’ Equity and (vi) Notes to Financial Statements

(1)

filed on Form 8-K on January 5, 2017 and incorporated herein by reference.

(2)

filed on Form 8-K on March 23, 2017 and incorporated herein by reference.

EX-31.1 2 v465791_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

I, Michael Favish, certify that:

I have reviewed this quarterly report on Form 10-Q of Guardion Health Sciences, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2017

/s/ Michael Favish

Michael Favish

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 v465791_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

I, John Townsend, certify that:

I have reviewed this quarterly report on Form 10-Q of Guardion Health Sciences, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2017	/s/ John Townsend
	John Townsend
	Controller and Chief Accounting Officer
	(Principal Accounting Officer)

EX-32.1 4 v465791_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ENACTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Guardion Health Sciences, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Michael Favish, Chief Executive Officer of the Company, and John Townsend, Controller and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 11, 2017	/s/ Michael Favish
	Michael Favish
	Chief Executive Officer
	(Principal Executive Officer)


May 11, 2017	/s/ John Townsend
	John Townsend
	Controller and Chief Accounting Officer
	(Principal Accounting Officer)

EX-101.INS 5 cik0001642375-20170331.xml XBRL INSTANCE DOCUMENT 0001642375 2016-01-01 2016-03-31 0001642375 2016-01-01 2016-12-31 0001642375 2017-01-01 2017-03-31 0001642375 2017-01-31 0001642375 2016-03-31 0001642375 2017-03-31 0001642375 2017-05-10 0001642375 2016-09-30 0001642375 2016-12-31 0001642375 2015-12-31 0001642375 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001642375 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-03-31 0001642375 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001642375 us-gaap:ConvertibleDebtSecuritiesMember 2016-01-01 2016-03-31 0001642375 cik0001642375:ConversionOfPreferredStockMember 2017-01-01 2017-03-31 0001642375 cik0001642375:ConversionOfPreferredStockMember 2016-01-01 2016-03-31 0001642375 us-gaap:OfficeEquipmentMember 2017-03-31 0001642375 us-gaap:OfficeEquipmentMember 2016-12-31 0001642375 us-gaap:ComputerEquipmentMember 2017-03-31 0001642375 us-gaap:ComputerEquipmentMember 2016-12-31 0001642375 us-gaap:OtherMachineryAndEquipmentMember 2017-03-31 0001642375 us-gaap:OtherMachineryAndEquipmentMember 2016-12-31 0001642375 us-gaap:LeaseholdImprovementsMember 2017-03-31 0001642375 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001642375 us-gaap:FurnitureAndFixturesMember 2017-03-31 0001642375 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001642375 us-gaap:PropertyPlantAndEquipmentMember 2017-01-01 2017-03-31 0001642375 us-gaap:PropertyPlantAndEquipmentMember 2016-01-01 2016-03-31 0001642375 us-gaap:ConvertibleNotesPayableMember cik0001642375:DueAugust2013Member cik0001642375:UnsecuredNotesPayableMember 2017-03-31 0001642375 us-gaap:ConvertibleNotesPayableMember cik0001642375:DueAugust2013Member cik0001642375:UnsecuredNotesPayableMember 2016-12-31 0001642375 us-gaap:ConvertibleNotesPayableMember cik0001642375:UnsecuredNotesPayableMember 2017-03-31 0001642375 us-gaap:ConvertibleNotesPayableMember cik0001642375:UnsecuredNotesPayableMember 2016-12-31 0001642375 us-gaap:ConvertibleNotesPayableMember us-gaap:UnsecuredDebtMember 2010-07-01 2010-07-31 0001642375 us-gaap:ConvertibleNotesPayableMember us-gaap:UnsecuredDebtMember 2010-07-31 0001642375 us-gaap:ConvertibleNotesPayableMember us-gaap:UnsecuredDebtMember 2017-03-31 0001642375 us-gaap:NotesPayableOtherPayablesMember us-gaap:UnsecuredDebtMember 2017-03-31 0001642375 us-gaap:NotesPayableOtherPayablesMember us-gaap:UnsecuredDebtMember 2016-12-31 0001642375 cik0001642375:DueNovember2016Member us-gaap:NotesPayableOtherPayablesMember 2017-03-31 0001642375 cik0001642375:DueNovember2016Member us-gaap:NotesPayableOtherPayablesMember 2016-12-31 0001642375 us-gaap:InvestorMember cik0001642375:DueSeptember2016Member us-gaap:UnsecuredDebtMember 2017-03-31 0001642375 us-gaap:InvestorMember cik0001642375:DueSeptember2016Member us-gaap:UnsecuredDebtMember 2016-12-31 0001642375 us-gaap:InvestorMember 2017-03-31 0001642375 us-gaap:InvestorMember 2016-12-31 0001642375 us-gaap:InvestorMember cik0001642375:TwoThousandSixteenIssuancesMember 2016-01-01 2016-12-31 0001642375 us-gaap:SeriesAPreferredStockMember 2017-03-31 0001642375 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001642375 us-gaap:CommonStockMember 2016-12-31 0001642375 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001642375 us-gaap:RetainedEarningsMember 2016-12-31 0001642375 us-gaap:CommonStockMember 2017-01-01 2017-03-31 0001642375 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-03-31 0001642375 us-gaap:RetainedEarningsMember 2017-01-01 2017-03-31 0001642375 us-gaap:CommonStockMember 2017-03-31 0001642375 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0001642375 us-gaap:RetainedEarningsMember 2017-03-31 0001642375 us-gaap:ConvertibleNotesPayableMember 2017-01-01 2017-03-31 0001642375 cik0001642375:DueMay2017Member us-gaap:NotesPayableOtherPayablesMember 2017-03-31 0001642375 cik0001642375:DueMay2017Member us-gaap:NotesPayableOtherPayablesMember 2016-12-31 0001642375 cik0001642375:PromissoryNoteMember us-gaap:InvestorMember 2017-01-31 0001642375 cik0001642375:PromissoryNoteMember us-gaap:InvestorMember 2017-01-01 2017-01-31 0001642375 cik0001642375:TwoThousandSixteenIssuancesMember 2017-03-31 0001642375 us-gaap:InvestorMember 2017-01-01 2017-03-31 0001642375 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-03-31 0001642375 us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-03-31 0001642375 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-12-31 0001642375 us-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-12-31 0001642375 us-gaap:RestrictedStockMember 2017-01-01 2017-03-31 0001642375 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001642375 us-gaap:WarrantMember 2017-03-31 0001642375 us-gaap:MinimumMember us-gaap:WarrantMember 2017-01-01 2017-03-31 0001642375 us-gaap:MaximumMember us-gaap:WarrantMember 2017-01-01 2017-03-31 0001642375 us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-03-31 0001642375 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2017-05-01 2017-05-10 0001642375 us-gaap:SeriesBPreferredStockMember 2017-03-31 0001642375 us-gaap:DividendDeclaredMember us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-03-31 0001642375 us-gaap:RestrictedStockMember 2017-03-31 0001642375 us-gaap:RestrictedStockMember us-gaap:ScenarioForecastMember 2017-04-01 2017-06-30 0001642375 us-gaap:InvestorMember 2017-01-01 2017-03-31 0001642375 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001642375 us-gaap:SubsequentEventMember 2017-04-01 2017-04-30 0001642375 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-03-31 0001642375 us-gaap:SeriesAPreferredStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:PreferredStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:SeriesAPreferredStockMember 2016-01-01 2016-03-31 0001642375 us-gaap:NotesPayableOtherPayablesMember cik0001642375:TwoThousandSixteenIssuancesMember 2016-01-01 2016-12-31 0001642375 us-gaap:NotesPayableOtherPayablesMember us-gaap:MinimumMember cik0001642375:TwoThousandSixteenIssuancesMember 2016-12-31 0001642375 us-gaap:NotesPayableOtherPayablesMember us-gaap:MaximumMember cik0001642375:TwoThousandSixteenIssuancesMember 2016-12-31 0001642375 cik0001642375:TwoThousandSixteenIssuancesMember 2016-12-31 0001642375 us-gaap:UnsecuredDebtMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001642375 us-gaap:UnsecuredDebtMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001642375 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:CommonStockMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001642375 us-gaap:CommonStockMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001642375 us-gaap:MinimumMember us-gaap:SeriesAPreferredStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:MinimumMember 2016-12-31 0001642375 us-gaap:NotesPayableOtherPayablesMember 2017-01-01 2017-03-31 0001642375 us-gaap:RestrictedStockMember 2016-12-31 0001642375 us-gaap:NotesPayableOtherPayablesMember 2017-01-01 2017-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

444850

62520

1914

1673

50024

43999

37732

29363

534520

137555

10470

98474

114020

643464

262045

433549

356467

59835

88290

133388

91483

45063

44323

797268

607619

25269

25046

21205658

20277882

-21387136

-20650207

643464

262045

-153804 -345574

125433

10251

16805

55941

29134

22633

14247

33308

14887

10239

10172

76736

103578

598913

623956

685888

737706

-652580

-722819

16431

226384

16431

226384

-669011

-949203

-0.03

-0.05

24760327

20966396

31841 0

36077

-736929

-949203

15545

8492

109455

13116

17148

240

-15

6025

10465

8369

-11361

77083

122454

-28456

-21920

-445576

-363862

1171

-1171

136000

827906

336300

382330

-28733

13850

-14883

99782

103623

8127

57158 240892

100000

25000

14000

0 124710 0 39774

90000

700000

41906

85300

153804

0.16 0.16

0.0248

0.0227

0.16

0.05 0.05 0.65 0.63 0 0

0.88

1.00

2983666

31250

2251166

1445811

3775266

43987

40679

6037

3320

2694

15277

145503

98357

15348

178705

163159

15545

8492

7325

5515

8220

2977

25000

20063

19323

45063

44323

25000

0.12

0.08

20063

15433

251

125433

10251

10000

14000

2805

16805

140000

2983666

1293512

133388

91483

10-Q false 2017-03-31 2017 Q1 Guardion Health Sciences, Inc. 0001642375 --12-31 Smaller Reporting Company 25443259

0.001

2000000

1705154

0.001

90000000

-345574

25046

20277882

-20650207

25046438

160781 163 160618 0 162500 700000 0 699300 0 0 0 0 31841 -31841 0 60 36017 -36077 59321

-669011

-153804

25269

21205658

-21387136

25268259

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Organization and Business Operations</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.75in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Organization and Business</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z<sup style="font-style:normal">®</sup> that replenishes and restores the macular protective pigment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Through March 31, 2017, the Company has had limited operations, but has been primarily engaged in research and development and capital raising. The Company has incurred significant expenditures for the development of the Company's products and intellectual property, which includes research and development of both medical foods and medical diagnostic equipment for the treatment of various eye diseases. The Company had limited revenue during the three months ended March 31, 2017 and 2016, all of which was generated by the sale of the Company’s proprietary product, Lumega-Z. In late 2014, the Company changed its focus from the dietary supplement category to the medical food category based on consultation with the Company’s intellectual property counsel and regulatory affairs consultants, as a result of which Lumega-Z is now categorized and sold as a medical food.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Going Concern and Liquidity</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $669,011 and utilized cash in operating activities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">445,576</font> during the three months ended March 31, 2017, and had a stockholders’ deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">153,804</font> as of March 31, 2017. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s auditors have also included explanatory language in their opinion that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">2.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Summary of Significant Accounting Policies</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Basis of Presentation and Use of Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s revenue is comprised of sales of medical foods to consumers through a direct sales/credit card process. Revenue is recognized when the risk of loss transfers to our customers, and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company allows for returns within 30 days of purchase. Product returns for the three months ended March 31, 2017 and 2016 were insignificant.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development Costs</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,239</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,172</font> for the three months ended March 31, 2017 and 2016, respectively.</font></div> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Stock-Based Compensation</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Stock-based payments to officers and directors, and to employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm whose input was utilized in determining the related per unit or share valuations of the Company’s equity instruments. Management used valuations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per unit or share in its fair value calculations for the periods between January 1, 2016 and September 30, 2016, and $0.88 per share for periods after September 30, 2016. The current valuation of $0.88 per share is lower than previous valuations due to the dilutive effect of the issuance of common shares as compensation during the periods. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. The Company considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Discount rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Sustainable growth rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Company survival probability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Liquidation value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Management considered business and market factors affecting the Company during the three-month periods ended March 31, 2017 and 2016, including capital raising efforts, its proprietary technology, and other factors. Based on this evaluation, management believes that $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share valuations are appropriate for accounting purposes for the periods ending March 31, 2017 and 2016, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes stock compensation expense on stock or unit purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock or units over the price paid for the stock or units.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company currently accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of March 31, 2017, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Net Loss per Share</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,983,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,251,166</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Estimated shares issuable upon conversion of convertible notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>31,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,445,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Shares issuable upon conversion of convertible preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,775,266</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,790,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,696,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 has not had any impact on the Company’s financial statement presentation or disclosures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">  Stock-Based Compensation</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Stock-based payments to officers and directors, and to employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm whose input was utilized in determining the related per unit or share valuations of the Company’s equity instruments. Management used valuations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per unit or share in its fair value calculations for the periods between January 1, 2016 and September 30, 2016, and $0.88 per share for periods after September 30, 2016. The current valuation of $0.88 per share is lower than previous valuations due to the dilutive effect of the issuance of common shares as compensation during the periods. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. The Company considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Discount rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Sustainable growth rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Company survival probability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Liquidation value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Management considered business and market factors affecting the Company during the three-month periods ended March 31, 2017 and 2016, including capital raising efforts, its proprietary technology, and other factors. Based on this evaluation, management believes that $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share valuations are appropriate for accounting purposes for the periods ending March 31, 2017 and 2016, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes stock compensation expense on stock or unit purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock or units over the price paid for the stock or units.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Net Loss per Share</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,983,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,251,166</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Estimated shares issuable upon conversion of convertible notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>31,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,445,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Shares issuable upon conversion of convertible preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,775,266</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,790,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,696,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div>Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Discount rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Sustainable growth rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Company survival probability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Liquidation value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

3696977

6790182

1.00

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">3.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> Inventories</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>43,987</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>40,679</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,037</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,320</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>50,024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>43,999</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.75in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Property and equipment consisted of the following: </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>98,357</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>98,357</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Testing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,503</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,503</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,348</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,348</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,277</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,277</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,694</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,694</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>277,179</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>277,179</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(178,705)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(163,159)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>98,474</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>114,020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

277179

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">5.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Convertible Notes Payable</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.75in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>  <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Year of issuance:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>2010 (due August 2013)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,063</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>Notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>45,063</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>44,323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2010, the Company issued an unsecured convertible note payable in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font>. The note carries simple interest at a rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% per annum and became due and payable on August 1, 2013. The outstanding amounts are convertible into shares of common stock of the Company at conversion prices of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.08</font> per share. This note is currently outstanding and past due, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,063</font> of accrued interest is recorded as of March 31, 2017.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Year of issuance:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>2010 (due August 2013)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,063</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>Notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>45,063</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>44,323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

100000

0.75

13040

100000

P120D

0.06

8000

10000

350

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Year of issuance:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>2016 (due September 2016)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>Promissory notes payable  related party, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>16,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

62500

22500

250000

48500

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A summary of the Company’s warrant activity is as follows: </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2,923,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>March 31, 2017, all exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2,983,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

162500

123750

0.92

0.88

60000 0 0

60000

51796

0.88

1.35

0.0161

0.75

2020-03-06 2020-03-08 12266

3256

700000

1.00

700000

0.06

0.75

0.75 165506

2441

The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation).

162500

143000

0.88

1160781

91485

25268259

25046438

P3Y

1705

700

1705

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="WIDTH: 48px"> <div><font style="FONT-SIZE: 10pt"><b>11.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><b>Subsequent Events</b></font></div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="left"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">During April 2017, the Company issued  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 175,000</font> shares of fully vested restricted common stock to consultants for services rendered. </font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.001

175000

2000000

700000

700.000

700000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">9.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> Stockholders’ Deficit</font></strong></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Preferred Stock</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Series A</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During 2016, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,170,000</font> shares of the Company’s Series A Senior Convertible Preferred Stock to various investors. The purchase price of the stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share, for an aggregate purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,170,000</font>. In addition, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 535,154</font> shares of its preferred stock with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">784,888</font> upon conversion of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">535,149</font> of notes payable and accrued interest. The stock has a stated value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share and accrues an annual dividend at the rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.60</font> per share. Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At the option of the holder, the Series A preferred stock (including accrued but unpaid dividends) may be converted into shares of the Company’s common stock commencing January 1, 2017 at $0.60 per share. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The preferred stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.</font> If not converted by September 30, 2019, the preferred stock (including accrued but unpaid dividends) shall automatically and mandatorily convert into shares of common stock at $0.60 per share. Such mandatory conversion shall be subject to either a registration statement having been filed with the Securities and Exchange Commission, including the common stock underlying the preferred stock, and being in effect, or all shares of underlying common stock being saleable under Rule 144 pursuant to the Securities Act without regard to volume limitations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The issuance of the 1,170,000 shares of convertible preferred stock gave rise to a beneficial conversion feature due to the stated conversion price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.60</font> per share being less than the market price of the shares at the issuance date as determined by a third-party valuation. The Company accounted for the beneficial conversion features in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series A Senior Convertible Preferred Stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">779,586</font> at December 31, 2016, which equals the amount by which the estimated fair value of the common stock issuable upon conversion of the issued preferred stock exceeded the proceeds from such issuances. The deemed dividend on the preferred stock is accreted using the effective interest method from the respective issuance dates through the earliest conversion date of January 1, 2017. The accretion of the deemed dividend for the year ended December 31, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">760,011</font>. The remaining balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,575</font>, representing the amount allocable to the January 1, 2017 earliest conversion date, was accreted in January 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Sale of the Company’s Series A Senior Convertible Preferred Stock was closed on December 31, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the three months ended March 31, 2017 the Company declared dividends of $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 33,631</font> to its Series A preferred shareholders which were paid through the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 56,065</font> shares of common stock.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">Series B</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">As of May 10, 2017, the Company had sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 700,000</font> shares of the Company’s Series B Convertible Preferred Stock to various investors. The purchase price of the stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share, for an aggregate purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">700,000</font>. The stock has a stated value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share and accrues an annual dividend at the rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6</font>% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share. Series B preferred stock is convertible commencing December 31, 2017, or earlier upon the approval of the Board of Directors, by the holder into common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation).</font> Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative. Series B preferred stock is senior to all Common Stock and junior to the Series A preferred stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The issuance of the Series B preferred stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.75 per share being less than the market price of the shares at the issuance date. In addition, warrants were issued to investors who had previously participated in the 2016 Series A preferred stock offering. The Company accounted for the beneficial conversion feature, including an allocation of proceeds for the warrants on a relative fair value basis, in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series B preferred stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">165,506</font> at March 31, 2017, which equals the amount by which the estimated fair value of the common stock issuable upon conversion of the issued preferred stock exceeded the proceeds from such issuances. The deemed dividend on the preferred stock is accreted using the effective interest method from the respective issuance dates through the earliest conversion date of December 31, 2017. The accretion of the deemed dividend for the three months ended March 31, 2017 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,266</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">During the three months ended March 31, 2017, the Company declared dividends of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,441</font> to its Series B preferred shareholders which were paid through the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,256</font> shares of common stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">Both classes of preferred stock will vote with the common stock on an “as converted” basis and have standard anti-dilution rights, exclusive of price protection. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, no distribution shall be made to the holders of any shares of common stock of the Company unless, prior thereto, the holders of all classes of preferred stock shall have received out of the available assets of the Company, whether capital or surplus, an amount equal to 100% of the stated value, plus any accrued and unpaid dividends thereon. If the assets of the Company are insufficient to pay in full such amounts due the holders of the preferred stock, then the entire assets shall be distributed ratably among the holders of the preferred stock in accordance with the respective preferences and amounts that would be payable on such shares of preferred stock if all amounts payable thereon were paid in full.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">Preferred shareholders of both series have unlimited piggyback registration rights. Holders of a majority of the shares of preferred stock (based on the $1.00 stated value) outstanding shall have the right to one demand registration during the three (3) years following the effective date of the Company’s registration statement under the Securities Exchange Act of 1934, so long as at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> of preferred stock was sold of that series, and at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> of the related class of preferred stock is still outstanding. This demand registration right will terminate when all shares of preferred stock have been converted into common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><strong><i><font style="FONT-SIZE: 10pt"> </font></i></strong> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">In the event of a merger or acquisition or change in control of the Company, the preferred stock (including all accrued but unpaid dividends) will be deemed converted into shares of common stock immediately prior to the closing of such a transaction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Common Stock</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During 2016 and prior, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,005,000</font> shares of restricted common stock for services rendered. These shares are subject to vesting requirements over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12</font> months and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,146,280</font>. As of December 31, 2016, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,652,500</font> of those shares with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,037,014</font> had vested, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 352,500</font> shares with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">109,266</font> remained to be vested.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">During the three months ended March 31, 2017, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 162,500</font> shares of restricted common stock to a service provider. These shares are subject to vesting requirements over 4 months and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">143,000</font> based on a valuation per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font> on the date of grant.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">During the three months ended March 31, 2017, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,160,781</font> of expense related to the vested portion of this restricted stock, and the remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">91,485</font> is expected to be recorded in the second quarter of 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Additional details of the Company’s restricted common stock are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Grant Date Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Per Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Non-vested, December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>352,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.13</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>162,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(123,750)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Non-vested, March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>391,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"> Warrants</font></i></strong></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">During the three months ended March 31, 2017, in connection with the Series B Convertible Preferred Stock offering discussed above, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000</font> warrants as additional incentive to investors who had previously invested in the Company’s Series A Senior Convertible Preferred Stock offering in 2016. These warrants are fully vested, are immediately exercisable at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share, and expire between March 6, 2020 and March 8, 2020. The warrants were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">51,796</font>, based upon the Black-Scholes option-pricing model, with a stock price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font>, volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 135</font>%, and an average risk-free interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.61</font>%.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font> <font style="FONT-SIZE: 10pt"> </font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company’s warrant activity is as follows: </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2,923,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>March 31, 2017, all exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2,983,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of March 31, 2017, the Company had an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,983,666</font> outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.37</font>, weighted average remaining life of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.4</font> years and aggregate intrinsic value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,293,512</font>, based upon a stock valuation of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font> per share. The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the warrants.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1705

1705154

1705

700

1705154

700000

0 0 0 0 0 700 0 700000 0 0 0

0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation and Use of Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

535149

1.00

1170000

1.00

1170000

535154

784888

0.08

0.60

The preferred stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.

779586 760011 19575

33631

56065

0.60

170000

0.04

0.09

10000

251

0.06

0.12

14000

2005000

2146280

109266

P9M

P12M

1652500

2037014

352500

0.37

P1Y4M24D

500000

250000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 48px"> <div><font style="FONT-SIZE: 10pt"><b>6.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><b>Promissory Notes</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Year of issuance:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>(a) 2016 (due November 2016)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>(b) 2017 (due May 2017)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>Promissory notes payable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>125,433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>10,251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">(a) In 2016, the Company issued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">170,000</font> of promissory notes to various outside investors, with simple interest rates ranging from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font>% - <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9</font>% and a weighted average term at issuance of approximately three months. As of March 31, 2017 and December 31, 2016, a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font> note remained outstanding and was past due, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">251</font> of accrued interest is recorded as of March 31, 2017 and December 31, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> (b) <font style="FONT-SIZE: 10pt">In January 2017, the Company issued a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> unsecured promissory note to an outside investor, with a term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 120</font> days and a fixed interest charge consisting of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6</font>% of the principal in cash plus 6% of the principal in shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share, or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,000</font> shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,040</font>, representing the total fair value of the charge, at the inception of the note. </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

352500

1.13

391250

1.09

2923666

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><font style="FONT-SIZE: 10pt"><b>8.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><b>Commitments and Contingencies</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed financial statements at March 31, 2017 with respect to such matters, including the matter noted below.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company recently received a payment demand from a former consultant to the Company alleging that he is owed $102,000 for unpaid services rendered. The Company is evaluating the claim and intends to respond to the former consultant’s demand in due course. If this matter results in the filing of a lawsuit against the Company, the Company intends to vigorously defend itself and, as well, will consider filing a counterclaim for damages against the former consultant.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

102000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Year of issuance:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>(a) 2016 (due November 2016)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>(b) 2017 (due May 2017)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div>Promissory notes payable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>125,433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>10,251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify">(a) In 2016, the Company issued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">170,000</font> of promissory notes to various outside investors, with simple interest rates ranging from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font>% - <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9</font>% and a weighted average term at issuance of approximately three months. As of March 31, 2017 and December 31, 2016, a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font> note remained outstanding and was past due, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">251</font> of accrued interest is recorded as of March 31, 2017 and December 31, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> (b) <font style="FONT-SIZE: 10pt">In January 2017, the Company issued a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> unsecured promissory note to an outside investor, with a term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 120</font> days and a fixed interest charge consisting of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6</font>% of the principal in cash plus 6% of the principal in shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share, or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,000</font> shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,040</font>, representing the total fair value of the charge, at the inception of the note.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

In 2016, the Company issued $170,000 of promissory notes to various outside investors, with simple interest rates ranging from 4% - 9% and a weighted average term at issuance of approximately three months. As of March 31, 2017 and December 31, 2016, a $10,000 note remained outstanding and was past due, and $350 and $251 of accrued interest is recorded as of March 31, 2017 and December 31, 2016. In January 2017, the Company issued a $100,000 unsecured promissory note to an outside investor, with a term of 120 days and a fixed interest charge consisting of 6% of the principal in cash plus 6% of the principal in shares of common stock at a price of $0.75 per share, or 8,000 shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded a accrued interest of $13,040 at the inception of the note, representing the total fair value of the charge, at the inception of the note.

EX-101.SCH 6 cik0001642375-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Statement of Stockholders' Equity Deficiency link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Condensed Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Organization and Business Operations link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Property and Equipment, net link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Promissory Notes link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Promissory Notes - Related Party link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Convertible Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Promissory Notes (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Promissory Notes - Related Party (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Organization and Business Operations (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Property and Equipment, net (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Convertible Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Convertible Notes Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Promissory Notes (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Promissory Notes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Promissory Notes - Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Promissory Notes - Related Party (Details Textual) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Stockholders' Deficit (Details 1) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Stockholders' Deficit (Details Textual) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 cik0001642375-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 cik0001642375-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 cik0001642375-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value, Total Cash Balance at beginning of period Balance at end of period Accounts Receivable, Net, Current, Total Accounts receivable Inventory, Net, Total Inventories Prepaid Expense and Other Assets, Current Current portion of deposits and prepaid expenses Assets, Current, Total Total current assets Prepaid Expense and Other Assets, Noncurrent Deposits and prepaid expenses, less current portion Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net, Total Assets, Total Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders’ Deficiency Liabilities and Stockholders’ Deficiency Liabilities, Current [Abstract] Current liabilities Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued liabilities Deferred Rent Credit, Current Accrued expenses and deferred lease costs Due to Officers or Stockholders, Current Due to related parties Convertible Notes Payable, Current Current portion of convertible notes payable Convertible notes payable - current portion, net Current portion of convertible notes payable - related party Other Notes Payable, Current Current portion of promissory notes payable Notes Payable, Related Parties, Current Current portion of promissory notes payable related party Liabilities, Current, Total Total current liabilities Commitments and Contingencies Commitments and contingencies Members’ and stockholders’equityDeficit [Abstract] Stockholders’ Deficiency Stockholders’ Deficiency Preferred Stock, Value, Issued Preferred stock Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding at September 30, 2015, as reported (unaudited) and as adjusted (unaudited) Common Stock, Value, Issued Common stock, $0.001 par value; 90,000,000 shares authorized; 25,268,259 and 25,046,438 shares issued and outstanding at March 31, 2017 and December 31, 2016 Common stock, $0.0001 par value; 90,000,000 shares authorized; 20,646,396 shares issued and outstanding, as reported (unaudited); 21,701,068 shares issued and outstanding, as adjusted (unaudited) Additional Paid in Capital, Common Stock Additional paid-in capital Additional paid-in capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Liabilities and Equity, Total Total liabilities and stockholders’ deficiency Total liabilities and stockholders’ deficiency Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Income Statement [Abstract] Revenue, Net Revenue Cost of Goods and Services Sold, Total Cost of goods sold Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development Selling and Marketing Expense, Total Sales and marketing General and Administrative Expense, Total General and administrative Operating Income (Loss), Total Loss from operations Interest and Debt Expense [Abstract] Other expenses: Interest Expense, Total Interest expense Operating Expenses, Total Total operating expenses Net Income (Loss) Attributable to Parent, Total Net loss Net loss Preferred Stock Dividends and Other Adjustments [Abstract] Adjustments related to Series A and Series B convertible preferred stock: Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common shareholders Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Members' Equity, Total Members' deficiency; 10,821,827 units outstanding at December 31, 2014 and 2013 Beginning Balance Ending Balance Common Unit, Outstanding Beginning Balance (in shares) Ending Balance (in shares) Stock Issued During Period Value Issued For Consulting Services Issuance of common stock for services Value of stock issued in consulting services. Stock Issued During Period Shares Issued For Consulting Services Issuance of common stock for services (in shares) Number of shares issued in consulting services. Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating Activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Amortization of Debt Discount (Premium) Amortization of debt discount Interest Expense, Debt Accrued interest expense included in notes payable Fair Value Adjustment of Warrants Fair value of warrants issued as post-maturity interest Share-based Compensation Stock-based compensation Share-based Compensation, Related Party Transactions Stock-based compensation - related parties The aggregate amount of noncash, equity-based compensation expenses from a related party transactions. Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] (Increase) decrease in - Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories, Total Inventories Increase (Decrease) in Prepaid Expense and Other Assets, Total Deposits and prepaid expenses Increase (Decrease) in Operating Liabilities [Abstract] Increase (decrease) in - Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued expenses Increase (Decrease) in Deferred Liabilities, Total Accrued and deferred rent costs Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing Activities Payments to Acquire Property, Plant, and Equipment, Total Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing Activities Proceeds from Convertible Debt Proceeds from issuance of convertible notes payable Proceeds from Related Party Debt Proceeds from issuance of promissory notes - related party Proceeds from Notes Payable Proceeds from issuance of promissory notes Repayments of Debt Payments on promissory notes Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from issuance of preferred stock Proceeds from (Repayments of) Related Party Debt Increase in due to related parties Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash: Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase (decrease) Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Total Cash paid for - Interest Income Taxes Paid, Net, Total Cash paid for - Income taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash financing activities: Fair Value of Warrants Issued In Connection With Promissory and Convertible Notes Payable Fair value of warrants issued in connection with promissory and convertible notes payable The fair value of warrants issued in connection with promissory and convertible notes payable. Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Stockholders' Equity Attributable to Parent, Total Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Basis Of Presentation And Use Of Estimates Policy [Policy Text Block] Disclosure of accounting policy for basis of presentation and use of estimates. Revenue Recognition, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Antidilutive Securities [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share Price Range [Axis] Antidilutive Securities, Name [Domain] Range [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Major Types of Debt and Equity Securities [Axis] Warrant [Member] Major Types of Debt and Equity Securities [Domain] Convertible Debt Securities [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events [Text Block] Schedule of Inventory, Current [Table Text Block] Inventory, Raw Materials, Net of Reserves Raw materials Inventory, Finished Goods and Work in Process, Net of Reserves, Total Finished goods Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Asset Class [Axis] Members And Stockholders Equity Deficit Total stockholders’ deficiency Total stockholders’ deficiency Total of all stockholders' and members equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Asset Class [Domain] Property, Plant and Equipment [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Type [Domain] Office Equipment [Member] Computer Equipment [Member] Other Machinery and Equipment [Member] Testing equipment [Member] Leasehold Improvements [Member] Furniture and Fixtures [Member] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Less accumulated depreciation and amortization Disclosure Text Block [Abstract] Debt Instrument [Axis] Debt Instrument, Name [Domain] Convertible Notes Payable [Member] Debt Disclosure [Text Block] Convertible Debt [Table Text Block] Repayments [Axis] Subsequent Event [Table] Long-term Debt, Type [Axis] Repayments [Domain] Due August 2013 [Member] Debt Instrument, Face Amount Interest Payable Accrued interest Accrued interest Subsequent Event Type [Axis] Award Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Title of Individual [Axis] Equity Award [Domain] Consultant [Axis] Relationship to Entity [Domain] Legal Entity [Axis] Consultant [Domain] Debt Conversion, Converted Instrument, Shares Issued Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Axis] Related Party Transaction [Domain] Income Statement Location [Axis] Due to Related Parties, Current Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Class of Warrant or Right, Outstanding Membership Units or Shares, Balance Membership Units or Shares, Balance Membership Units or Shares, Outstanding Warrants Granted Membership Units or Shares, Granted Number of warrants options (or share units) granted during the period. Warrants Cancelled Membership Units or Shares, Forfeitures Number of warrants options (or share units) cancelled during the period. EX-101.PRE 10 cik0001642375-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2017	May 10, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	0001642375
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,443,259

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 444,850	$ 62,520
Accounts receivable	1,914	1,673
Inventories	50,024	43,999
Current portion of deposits and prepaid expenses	37,732	29,363
Total current assets	534,520	137,555
Deposits and prepaid expenses, less current portion	10,470	10,470
Property and equipment, net	98,474	114,020
Total assets	643,464	262,045
Current liabilities
Accounts payable and accrued liabilities	433,549	356,467
Accrued expenses and deferred lease costs	59,835	88,290
Due to related parties	133,388	91,483
Current portion of convertible notes payable	45,063	44,323
Current portion of promissory notes payable	125,433	10,251
Current portion of promissory notes payable related party	0	16,805
Total current liabilities	797,268	607,619
Commitments and contingencies
Stockholders’ Deficiency
Common stock, $0.001 par value; 90,000,000 shares authorized; 25,268,259 and 25,046,438 shares issued and outstanding at March 31, 2017 and December 31, 2016	25,269	25,046
Additional paid-in capital	21,205,658	20,277,882
Accumulated deficit	(21,387,136)	(20,650,207)
Total stockholders’ deficiency	(153,804)	(345,574)
Total liabilities and stockholders’ deficiency	643,464	262,045
Series A Preferred Stock [Member]
Stockholders’ Deficiency
Preferred stock	1,705	1,705
Series B Preferred Stock [Member]
Stockholders’ Deficiency
Preferred stock	$ 700	$ 0

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	25,268,259	25,046,438
Common Stock, Shares, Outstanding	25,268,259	25,046,438
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	2,000,000	2,000,000
Preferred Stock, Shares Issued	1,705,154	1,705,154
Preferred Stock, Shares Outstanding	1,705,154	1,705,154
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	2,000,000	2,000,000
Preferred Stock, Shares Issued	700,000	700,000
Preferred Stock, Shares Outstanding	700.000	700,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations - USD ($)	3 Months Ended
Condensed Statements of Operations - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Revenue	$ 55,941	$ 29,134
Cost of goods sold	22,633	14,247
Gross profit	33,308	14,887
Operating expenses
Research and development	10,239	10,172
Sales and marketing	76,736	103,578
General and administrative	598,913	623,956
Total operating expenses	685,888	737,706
Loss from operations	(652,580)	(722,819)
Other expenses:
Interest expense	16,431	226,384
Total other expenses	16,431	226,384
Net loss	(669,011)	(949,203)
Adjustments related to Series A and Series B convertible preferred stock:
Accretion of deemed dividend	(31,841)	0
Dividend declared	(36,077)	0
Net loss attributable to common shareholders	$ (736,929)	$ (949,203)
Net loss per common share - basic and diluted	$ (0.03)	$ (0.05)
Weighted average common shares outstanding - basic and diluted	24,760,327	20,966,396

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Statement of Stockholders' Equity Deficiency - 3 months ended Mar. 31, 2017 - USD ($)	Total	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Beginning Balance at Dec. 31, 2016	$ (345,574)	$ 1,705	$ 0	$ 25,046	$ 20,277,882	$ (20,650,207)
Beginning Balance (in shares) at Dec. 31, 2016		1,705,154	0	25,046,438
Issuance of common stock for services	160,781	$ 0	$ 0	$ 163	160,618	0
Issuance of common stock for services (in shares)		0	0	162,500
Issuance of preferred stock	700,000	$ 0	$ 700	$ 0	699,300	0
Issuance of preferred stock (in shares)		0	700,000	0
Accretion of beneficial conversion feature on preferred stock	0			$ 0	31,841	(31,841)
Dividend on preferred stock	0	$ 0	$ 0	$ 60	36,017	(36,077)
Dividend on preferred stock (in shares)		0	0	59,321
Net loss	(669,011)	$ 0	$ 0	$ 0	0	(669,011)
Ending Balance at Mar. 31, 2017	$ (153,804)	$ 1,705	$ 700	$ 25,269	$ 21,205,658	$ (21,387,136)
Ending Balance (in shares) at Mar. 31, 2017		1,705,154	700,000	25,268,259

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows - USD ($)	3 Months Ended
Condensed Statements of Cash Flows - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Operating Activities
Net loss	$ (669,011)	$ (949,203)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15,545	8,492
Amortization of debt discount	0	109,455
Accrued interest expense included in notes payable	13,116	17,148
Fair value of warrants issued as post-maturity interest	0	99,782
Stock-based compensation	103,623	8,127
Stock-based compensation - related parties	57,158	240,892
(Increase) decrease in -
Accounts receivable	(240)	15
Inventories	(6,025)	(10,465)
Deposits and prepaid expenses	(8,369)	11,361
Increase (decrease) in -
Accounts payable and accrued expenses	77,083	122,454
Accrued and deferred rent costs	(28,456)	(21,920)
Net cash used in operating activities	(445,576)	(363,862)
Investing Activities
Purchase of property and equipment	0	(1,171)
Net cash used in investing activities	0	(1,171)
Financing Activities
Proceeds from issuance of convertible notes payable	0	136,000
Proceeds from issuance of promissory notes - related party	0	90,000
Proceeds from issuance of promissory notes	100,000	25,000
Payments on promissory notes	(14,000)	0
Proceeds from issuance of preferred stock	700,000	0
Increase in due to related parties	41,906	85,300
Net cash provided by financing activities	827,906	336,300
Cash:
Net increase (decrease)	382,330	(28,733)
Balance at beginning of period	62,520	13,850
Balance at end of period	444,850	(14,883)
Supplemental disclosure of cash flow information:
Cash paid for - Interest	0	0
Cash paid for - Income taxes	0	0
Non-cash financing activities:
Fair value of warrants issued in connection with promissory and convertible notes payable	0	124,710
Beneficial conversion feature associated with promissory and convertible notes payable	$ 0	$ 39,774

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Business Operations

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.	Organization and Business Operations

Organization and Business

Going Concern and Liquidity

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2.	Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

Revenue Recognition

The Company allows for returns within 30 days of purchase. Product returns for the three months ended March 31, 2017 and 2016 were insignificant.

Research and Development Costs

Stock-Based Compensation

	Three Months Ended March 31,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Income Taxes

Net Loss per Share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	March 31,
	2017		2016
Warrants		2,983,666		2,251,166
Estimated shares issuable upon conversion of convertible notes payable		31,250		1,445,811
Shares issuable upon conversion of convertible preferred stock		3,775,266		-
		6,790,182		3,696,977

Recent Accounting Pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

3.	Inventories

Inventories consisted of the following:

	March 31,		December 31,
	2017		2016
Raw materials	$	43,987	$	40,679
Finished goods		6,037		3,320
	$	50,024	$	43,999

XML 20 R10.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

4.	Property and Equipment, net

Property and equipment consisted of the following:

	March 31,		December 31,
	2017		2016
Leasehold improvements	$	98,357	$	98,357
Testing equipment		145,503		145,503
Furniture and fixtures		15,348		15,348
Computer equipment		15,277		15,277
Office equipment		2,694		2,694
		277,179		277,179
Less accumulated depreciation and amortization		(178,705)		(163,159)
	$	98,474	$	114,020

XML 21 R11.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

3 Months Ended

Mar. 31, 2017

Convertible Notes Payable [Member]

Debt Disclosure [Text Block]

5.	Convertible Notes Payable

	March 31,		December 31,
Year of issuance:	2017		2016
2010 (due August 2013)	$	25,000	$	25,000
Accrued interest		20,063		19,323
Notes payable	$	45,063	$	44,323

XML 22 R12.htm IDEA: XBRL DOCUMENT

Promissory Notes

3 Months Ended

Mar. 31, 2017

Promissory Notes Payable [Member]

Debt Disclosure [Text Block]

6.	Promissory Notes

	March 31,		December 31,
Year of issuance:	2017		2016
(a) 2016 (due November 2016)	$	10,000	$	10,000
(b) 2017 (due May 2017)		100,000		-
Accrued interest		15,433		251
Promissory notes payable, net	$	125,433	$	10,251

XML 23 R13.htm IDEA: XBRL DOCUMENT

Promissory Notes - Related Party

3 Months Ended

Mar. 31, 2017

Investor [Member]

Debt Disclosure [Text Block]

7.	Promissory Notes – Related Party

	March 31,		December 31,
Year of issuance:	2017		2016
2016 (due September 2016)	$	-	$	14,000
Accrued interest		-		2,805
Promissory notes payable – related party, net	$	-	$	16,805

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

8.	Commitments and Contingencies

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

3 Months Ended

Mar. 31, 2017

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

9.	Stockholders’ Deficit

Preferred Stock

Series A

Sale of the Company’s Series A Senior Convertible Preferred Stock was closed on December 31, 2016.

During the three months ended March 31, 2017 the Company declared dividends of $ 33,631 to its Series A preferred shareholders which were paid through the issuance of 56,065 shares of common stock.

Series B

During the three months ended March 31, 2017, the Company declared dividends of $2,441 to its Series B preferred shareholders which were paid through the issuance of 3,256 shares of common stock.

Common Stock

Additional details of the Company’s restricted common stock are as follows:

			Weighted Average
			Grant Date Fair Value
	Number of Shares		Per Share
Non-vested, December 31, 2016		352,500		1.13
Issued		162,500		0.88
Vested		(123,750)		0.92
Forfeited		-		-
Non-vested, March 31, 2017		391,250	$	1.09

Warrants

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2016		2,923,666
Granted		60,000
Forfeitures		-
Exercised		-
March 31, 2017, all exercisable		2,983,666

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2017

10.

Related Party Transactions

XML 27 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2017

Subsequent Events [Abstract]

Subsequent Events [Text Block]

11.

Subsequent Events

During April 2017, the Company issued 175,000 shares of fully vested restricted common stock to consultants for services rendered.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]

Basis of Presentation and Use of Estimates

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company allows for returns within 30 days of purchase. Product returns for the three months ended March 31, 2017 and 2016 were insignificant.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Stock-Based Compensation

	Three Months Ended March 31,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Income Tax, Policy [Policy Text Block]

Income Taxes

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	March 31,
	2017		2016
Warrants		2,983,666		2,251,166
Estimated shares issuable upon conversion of convertible notes payable		31,250		1,445,811
Shares issuable upon conversion of convertible preferred stock		3,775,266		-
		6,790,182		3,696,977

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:

	Three Months Ended March 31,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	March 31,
	2017		2016
Warrants		2,983,666		2,251,166
Estimated shares issuable upon conversion of convertible notes payable		31,250		1,445,811
Shares issuable upon conversion of convertible preferred stock		3,775,266		-
		6,790,182		3,696,977

XML 30 R20.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consisted of the following:

	March 31,		December 31,
	2017		2016
Raw materials	$	43,987	$	40,679
Finished goods		6,037		3,320
	$	50,024	$	43,999

XML 31 R21.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consisted of the following:

	March 31,		December 31,
	2017		2016
Leasehold improvements	$	98,357	$	98,357
Testing equipment		145,503		145,503
Furniture and fixtures		15,348		15,348
Computer equipment		15,277		15,277
Office equipment		2,694		2,694
		277,179		277,179
Less accumulated depreciation and amortization		(178,705)		(163,159)
	$	98,474	$	114,020

XML 32 R22.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Tables)

3 Months Ended

Mar. 31, 2017

Convertible Notes Payable [Member]

Convertible Debt [Table Text Block]

	March 31,		December 31,
Year of issuance:	2017		2016
2010 (due August 2013)	$	25,000	$	25,000
Accrued interest		20,063		19,323
Notes payable	$	45,063	$	44,323

XML 33 R23.htm IDEA: XBRL DOCUMENT

Promissory Notes (Tables)

3 Months Ended

Mar. 31, 2017

Promissory Notes Payable [Member]

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	March 31,		December 31,
Year of issuance:	2017		2016
(a) 2016 (due November 2016)	$	10,000	$	10,000
(b) 2017 (due May 2017)		100,000		-
Accrued interest		15,433		251
Promissory notes payable, net	$	125,433	$	10,251

XML 34 R24.htm IDEA: XBRL DOCUMENT

Promissory Notes - Related Party (Tables)

3 Months Ended

Mar. 31, 2017

Investor [Member]

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	March 31,		December 31,
Year of issuance:	2017		2016
2016 (due September 2016)	$	-	$	14,000
Accrued interest		-		2,805
Promissory notes payable – related party, net	$	-	$	16,805

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Tables)

3 Months Ended

Mar. 31, 2017

Stockholders' Equity Note [Abstract]

Nonvested Restricted Stock Shares Activity [Table Text Block]

Additional details of the Company’s restricted common stock are as follows:

			Weighted Average
			Grant Date Fair Value
	Number of Shares		Per Share
Non-vested, December 31, 2016		352,500		1.13
Issued		162,500		0.88
Vested		(123,750)		0.92
Forfeited		-		-
Non-vested, March 31, 2017		391,250	$	1.09

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2016		2,923,666
Granted		60,000
Forfeitures		-
Exercised		-
March 31, 2017, all exercisable		2,983,666

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 36 R26.htm IDEA: XBRL DOCUMENT

Organization and Business Operations (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	$ (445,576)	$ (363,862)
Stockholders' Equity Attributable to Parent, Total	153,804
Net Income (Loss) Attributable to Parent, Total	$ (669,011)	$ (949,203)

XML 37 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Discount rate	16.00%	16.00%
Risk free rate	2.48%	2.27%
Rate of return	16.00%	16.00%
Sustainable growth rate	5.00%	5.00%
Company survival probability	65.00%	63.00%
Liquidation value	$ 0	$ 0

XML 38 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,790,182	3,696,977
Conversion of Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,775,266	0
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	31,250	1,445,811
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,983,666	2,251,166

XML 39 R29.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Sep. 30, 2016
Research and Development Expense	$ 10,239	$ 10,172
Share Price	$ 0.88	$ 1.00	$ 1.00

XML 40 R30.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Raw materials	$ 43,987	$ 40,679
Finished goods	6,037	3,320
Inventory, Net, Total	$ 50,024	$ 43,999

XML 41 R31.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment, Gross, Total	$ 277,179	$ 277,179
Less accumulated depreciation and amortization	(178,705)	(163,159)
Property, Plant and Equipment, Net, Total	98,474	114,020
Office Equipment [Member]
Property, Plant and Equipment, Gross, Total	2,694	2,694
Computer Equipment [Member]
Property, Plant and Equipment, Gross, Total	15,277	15,277
Testing equipment [Member]
Property, Plant and Equipment, Gross, Total	145,503	145,503
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Total	98,357	98,357
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross, Total	$ 15,348	$ 15,348

XML 42 R32.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details Textual) - USD ($)	3 Months Ended
Property and Equipment, net (Details Textual) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 15,545	$ 8,492
Research and Development Expense	10,239	10,172
General and Administrative Expense, Total	598,913	623,956
Property, Plant and Equipment [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total	15,545	8,492
Research and Development Expense	7,325	5,515
General and Administrative Expense, Total	$ 8,220	$ 2,977

XML 43 R33.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details) - Convertible Notes Payable [Member] - Unsecured Notes Payable [Member] - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Accrued interest	$ 20,063	$ 19,323
Notes payable	45,063	44,323
Due August 2013 [Member]
Debt Instrument, Face Amount	$ 25,000	$ 25,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
Convertible Notes Payable (Details Textual) - USD ($)	Jul. 31, 2010	Mar. 31, 2017	Mar. 31, 2016
Proceeds from Convertible Debt		$ 0	$ 136,000
Convertible Notes Payable [Member] \| Unsecured Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Convertible, Conversion Price	$ 0.08
Proceeds from Convertible Debt	$ 25,000
Interest Payable		$ 20,063

XML 45 R35.htm IDEA: XBRL DOCUMENT

Promissory Notes (Details) - Notes Payable, Other Payables [Member] - USD ($)

Mar. 31, 2017

Dec. 31, 2016

Unsecured Promissory Notes [Member]

Accrued interest

$ 15,433

$ 251

Promissory notes payable, net

125,433

10,251

2016 (due November 2016)

Debt Instrument, Face Amount

^[1]

10,000

2017 (due May 2017) [Member]

Debt Instrument, Face Amount

^[2]

$ 100,000

$ 0

[1]

[2]

In January 2017, the Company issued a $100,000 unsecured promissory note to an outside investor, with a term of 120 days and a fixed interest charge consisting of 6% of the principal in cash plus 6% of the principal in shares of common stock at a price of $0.75 per share, or 8,000 shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded a accrued interest of $13,040 at the inception of the note, representing the total fair value of the charge, at the inception of the note.

XML 46 R36.htm IDEA: XBRL DOCUMENT

Promissory Notes (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
Promissory Notes (Details Textual) - USD ($)	Jan. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Proceeds from Notes Payable		$ 100,000	$ 25,000
Short-term Debt		14,000
2016 Issuances [Member]
Short-term Debt		10,000		$ 10,000
Interest Payable, Current		$ 350		251
2016 Issuances [Member] \| Investor [Member]
Proceeds from Notes Payable				140,000
Notes Payable, Other Payables [Member] \| 2016 Issuances [Member]
Proceeds from Notes Payable				$ 170,000
Notes Payable, Other Payables [Member] \| Minimum [Member] \| 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage				4.00%
Notes Payable, Other Payables [Member] \| Maximum [Member] \| 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage				9.00%
Promissory Note [Member] \| Investor [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.75
Interest Payable, Current	$ 13,040
Debt Instrument, Face Amount	$ 100,000
Debt Instrument, Term	120 days
Short-term Debt, Percentage Bearing Fixed Interest Rate	6.00%
Debt Conversion, Converted Instrument, Shares Issued	8,000

XML 47 R37.htm IDEA: XBRL DOCUMENT

Promissory Notes - Related Party (Details) - Investor [Member] - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Accrued interest	$ 0	$ 2,805
Promissory notes payable - related party, net	0	16,805
2016 (due September 2016) [Member] \| Unsecured Debt [Member]
Accrued interest	$ 0	$ 14,000

XML 48 R38.htm IDEA: XBRL DOCUMENT

Promissory Notes - Related Party (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Proceeds from Notes Payable	$ 100,000	$ 25,000
Short-term Debt	14,000
2016 Issuances [Member]
Short-term Debt	$ 10,000		$ 10,000
Minimum [Member] \| Unsecured Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate			6.00%
Maximum [Member] \| Unsecured Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate			12.00%
Investor [Member] \| 2016 Issuances [Member]
Proceeds from Notes Payable			$ 140,000

XML 49 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual)	3 Months Ended
Commitments and Contingencies (Details Textual)	Mar. 31, 2017 USD ($)
Loss Contingency, Damages Sought, Value	$ 102,000

XML 50 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2017 $ / shares shares
Number of Shares, Beginning Balance \| shares	352,500
Number of Shares, Issued \| shares	162,500
Number of Shares, Vested \| shares	(123,750)
Number of Shares, Forfeited \| shares	0
Number of Shares, Ending Balance \| shares	391,250
Weighted Average Grant Date Fair Value Per Share, Beginning Balance \| $ / shares	$ 1.13
Weighted Average Grant Date Fair Value Per Share, Issued \| $ / shares	0.88
Weighted Average Grant Date Fair Value Per Share, Vested \| $ / shares	0.92
Weighted Average Grant Date Fair Value Per Share, Forfeited \| $ / shares	0
Weighted Average Grant Date Fair Value Per Share, Ending Balance \| $ / shares	$ 1.09

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details 1)	3 Months Ended
Stockholders' Deficit (Details 1)	Mar. 31, 2017 shares
Class of Warrant or Right [Line Items]
Membership Units or Shares, Balance	2,923,666
Membership Units or Shares, Granted	60,000
Membership Units or Shares, Forfeitures	0
Membership Units or Shares, Exercised	0
Membership Units or Shares, Balance	2,983,666

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details Textual) - USD ($)		1 Months Ended	3 Months Ended			12 Months Ended
Stockholders' Deficit (Details Textual) - USD ($)	May 10, 2017	Apr. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Jan. 31, 2017	Sep. 30, 2016
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.75
Class of Warrant or Right, Outstanding				2,983,666		2,923,666
Warrants Intrinsic Value				$ 1,293,512
Share Price				$ 0.88	$ 1.00			$ 1.00
Accretion of Dividends				$ 12,266		$ 760,011	$ 19,575
Debt Conversion, Original Debt, Amount						535,149
Warrants Issued				$ 60,000
Deemed Dividend						$ 779,586
Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.37
Fair Value Assumptions, Expected Volatility Rate				135.00%
Fair Value Assumptions, Risk Free Interest Rate				1.61%
Warrants Weighted Average Remaining Life				1 year 4 months 24 days
Share Price				$ 0.88
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 51,796
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Issued for Services				162,500
Share Price				$ 0.88
Warrants Term						3 years
Restricted Stock or Unit Expense				$ 1,160,781
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				$ 143,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number				391,250		352,500
Restricted Stock [Member] \| Scenario, Forecast [Member]
Class of Warrant or Right [Line Items]
Restricted Stock or Unit Expense			$ 91,485
Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues						2,005,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value						$ 109,266
Stock Issued						$ 2,146,280
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						1,652,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value						$ 2,037,014
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number						352,500
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Shares Issued						535,154
Stock Issued						$ 784,888
Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Shares Issued		175,000
Minimum [Member]
Class of Warrant or Right [Line Items]
Accretion of Dividends						$ 250,000
Minimum [Member] \| Warrant [Member]
Class of Warrant or Right [Line Items]
Warrant Expiration Date				Mar. 06, 2020
Minimum [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period						9 months
Maximum [Member] \| Warrant [Member]
Class of Warrant or Right [Line Items]
Warrant Expiration Date				Mar. 08, 2020
Maximum [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period						12 months
Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Shares Issued, Price Per Share						1.00
Share Price						$ 1.00
Stock Issued During Period, Shares, New Issues						1,170,000
Stock Issued During Period, Value, New Issues						$ 1,170,000
Preferred Stock, Dividend Rate, Percentage						8.00%
Preferred Stock, Dividends Per Share, Declared				$ 0.60		$ 0.60
Convertible Preferred Stock, Terms of Conversion						The preferred stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.
Common Stock Dividends, Shares					56,065
Dividends, Preferred Stock, Stock				$ 33,631
Series A Preferred Stock [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues						$ 500,000
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Shares Issued, Price Per Share				$ 1.00
Stock Issued During Period, Value, New Issues				$ 700,000
Preferred Stock, Dividend Rate, Percentage				6.00%
Preferred Stock, Dividends Per Share, Declared				$ 0.75
Convertible Preferred Stock, Conversion Price				$ 0.75
Convertible Preferred Stock, Terms of Conversion				The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation).
Common Stock Dividends, Shares				3,256
Deemed Dividend				$ 165,506
Series B Preferred Stock [Member] \| Dividend Declared [Member]
Class of Warrant or Right [Line Items]
Dividends, Preferred Stock, Stock				$ 2,441
Series B Preferred Stock [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues	700,000

XML 53 R43.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 133,388	$ 91,483
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments to Employees	22,500	48,500
General and Administrative Expense [Member] \| Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Officers' Compensation	$ 62,500	$ 250,000

XML 54 R44.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Textual)	1 Months Ended
Subsequent Events (Details Textual)	Apr. 30, 2017 shares
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	175,000

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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